Inclusion complex of aprepitant with cyclodextrin: Evaluation of physico-chemical and pharmacokinetic properties

Drug Development and Industrial Pharmacy

Volumn 39, Issue 11, 2013, Pages 1783-1792

  Ridhurkar, Devendra N ^a   Ansari, Khalid Akhter ^a   Kumar, Deepak ^a   Kaul, Neeraj S ^a   Krishnamurthy, T ^a   Dhawan, Sanju ^a   Pillai, Raviraj ^a  

^a DR REDDY'S LABORATORIES LTD   (India)

Author keywords

Aprepitant; Bioequivalence; Complexation; Cyclodextrin; Nanoparticles

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; AEROSIL; APREPITANT; BETA CYCLODEXTRIN; CROSPOVIDONE; HYDROXYL GROUP; HYDROXYPROPYLCELLULOSE; MICROCRYSTALLINE CELLULOSE; SUCROSE; TALC; TERT BUTYL ALCOHOL; TEXAPON;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CHEMICAL INTERACTION; COMPLEX FORMATION; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; CROSSOVER PROCEDURE; DIFFERENTIAL SCANNING CALORIMETRY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DOSAGE FORM COMPARISON; DRUG HALF LIFE; DRUG RELEASE; DRUG SOLUBILITY; DRUG STABILITY; FEASIBILITY STUDY; HUMAN; IN VITRO STUDY; INFRARED SPECTROSCOPY; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; TIME TO MAXIMUM PLASMA CONCENTRATION; X RAY POWDER DIFFRACTION;

ADULT; ANTIEMETICS; BIOLOGICAL AVAILABILITY; CROSS-OVER STUDIES; CYCLODEXTRINS; DRUG CARRIERS; DRUG COMPOUNDING; DRUG STABILITY; DRUG STORAGE; EXCIPIENTS; FEASIBILITY STUDIES; HALF-LIFE; HUMANS; INTESTINAL ABSORPTION; MALE; MECHANICAL PHENOMENA; MORPHOLINES; NANOPARTICLES; NEUROKININ-1 RECEPTOR ANTAGONISTS; PHYSICOCHEMICAL PHENOMENA; SEQUESTERING AGENTS; SOLUBILITY;

EID: 84885598581     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639045.2012.737331     Document Type: Article

References (33)

1. Cocquyt V, Van Belle S, Reinhardt RR, Decramer ML, OBrien M, Schellens JH et al (2001). Comparison of L-758,298, a prodrug for the selective neurokinin-1 antagonist, L-754,030, with ondansetron for the prevention of cisplatin-induced emesis. Eur J Cancer, 37:835-842
2. Navari RM, Reinhardt RR, Gralla RJ, Kris MG, Hesketh PJ, Khojasteh A et al. (1999). Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group. N Engl J Med, 340:190-195
3. Campos D, Pereira JR, Reinhardt RR, Carracedo C, Poli S, Vogel C et al (2001). Prevention of cisplatin-induced emesis by the oral neurokinin-1 antagonist, MK-869, in combination with granisetron and dexamethasone or with dexamethasone alone. J Clin Oncol, 19:1759-1767
4. Van Belle S, Lichinitser MR, Navari RM, Garin AM, Decramer ML, Riviere A et al. (2002). Prevention of cisplatin-induced acute and delayed emesis by the selective neurokinin-1 antagonists, L-758,298 and MK-869. Cancer, 94:3032-3041
5. Antiemetic Subcommittee of the Multinational Association of supportive care in Cancer (MASCC). (1998). Prevention of chemotherapy and radiotherapy-induced emesis: Results of the Perugia Consensus Conference. Ann Oncol, 9:1022-1029
6. Roila F, Tonato M, Ballatori E, Del Favero A. (1996). Comparative studies of various antiemetic regimens. Support Care Cancer, 4:270-280
7. Grunberg SM, Deuson RR, Mavros P, Geling O, Hansen M, Cruciani G et al. (2004). Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer, 100:2261-2268
8. Wu Y, Loper A, Landis E, Hettrick L, Novak L, Lynn K et al. (2004). The role of biopharmaceutics in the development of a clinical nanoparticle formulation of MK-0869: A Beagle dog model predicts improved bioavailability and diminished food effect on absorption in human. Int J Pharm, 285:135-146
9. US FDA. (2000). Guidance for Industry: Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system
10. Löbenberg R, Amidon GL. (2000). Modern bioavailability, bioequivalence and biopharmaceutics classification system. New scientific approaches to international regulatory standards. Eur J Pharm Biopharm, 50:3-12
11. Yasushi S, Ekarat J, Filippos K, Christos R, Jennifer BD. (2010). Forecasting in vivo oral absorption and food effect of micronized and nanosized aprepitant formulations in humans. Eur J Pharm Biopharm, 76:95-104
12. Dhananjay SS, Seshasai MM, Gowthamrajanb K, Giriraj KT, Rajesh V, Parchuri SR. (2010). Optimization of formulation and process variable of nanosuspension: An industrial perspective. Int J Pharm, 402:213-220
13. Müller RH, Jacobs C, Kayser O. (2001). Nanosuspensions as particulate drug formulations in therapy. Rationale for development and what we can expect for the future. Adv Drug Deliv Rev, 47:3-19
14. Basa S, Muniyappan T, Karatgi P, Prabhu R, Pillai R. (2008). Production and in vitro characterization of solid dosage form incorporating drug nanoparticles. Drug Dev Ind Pharm, 34:1209-1218
15. Aungst BJ. (1993). Novel formulation strategies for improving oral bioavailability of drugs with poor membrane permeation or presystemic metabolism. J Pharm Sci, 82:979-987
16. Humberstone AJ, Charman WN. (1997). Lipid-based vehicles for the oral delivery of poorly water soluble drugs. Adv Drug Deliv Rev, 25:103-128
17. Constantinides PP. (1995). Lipid microemulsions for improving drug dissolution and oral absorption: Physical and biopharmaceutical aspects. Pharm Res, 12:1561-1572
18. Pouton CW. (2000). Lipid formulations for oral administration of drugs: Non-emulsifying, self-emulsifying and selfmicroemulsifying drug delivery systems. Eur J Pharm Sci, 11 Suppl2:S93-S98
19. Davis ME, Brewster ME. (2004). Cyclodextrin-based pharmaceutics: Past, present and future. Nat Rev Drug Discov, 3:1023-1035
20. Davis ME. (2009). Design and development of IT-101, a cyclodextrin-containing polymer conjugate of camptothecin. Adv Drug Deliv Rev, 61:1189-1192
21. Vijaykumar N, Pradeep K, Srinivasarao P, Raviraj P. (2010). Drug product development and pharmacological evaluation of a sparingly soluble novel camptothecin analog for peroral administration. Drug Delivery, 18:294-303
22. Loftsson T, Brewster ME. (1996). Pharmaceutical applications of cyclodextrins. 1. Drug solubilization and stabilization. J Pharm Sci, 85:1017-1025
23. Riley CM, Rytting JH, Kral MA. (1991). Higuchi Takeru: A memorial tribute, equilibria and thermodynamics. Vol. 3. Lawrence: Allen Press
24. Tomasik P, Schilling CH. (1998). Complexes of starch with inorganic guests. In: Horton D, ed. Advances in Carbohydrate Chemistry and Biochemistry. Vol. 53. San Diego: Academic Press, 263-243
25. Tomasik P, Schilling CH. (1998). Complexes of starch with organic guests. In: Horton D, ed. Advances in Carbohydrate Chemistry and Biochemistry. Vol. 53. San Diego: Academic Press, 345-426
26. Loftsson T, Hreinsdósttir D, Másson M. (2005). Evaluation of cyclodextrin solubilization of drugs. Int J Pharm, 302:18-28
27. Chatjigakis AK, Donze C, Coleman AW. (1992). Solubility behavior of B-cyclodextrin in water/cosolvent mixtures. Anal Chem, 64:1632-1634
28. Loftsson T, Hreindóstter D, Másson M. (2007). The complexation efficiency. J Incl Phenom Macrocycl Chem, 57:545-552
29. Ekarat J, Niels J, Christos R, Jennifer BD. (2008). Dissolution Media Simulating Conditions in the Proximal Human Gastrointestinal Tract: An Update. Pharm Res, 25:1663-1676
30. Manolikar MK, Sawant MR. (2003). Study of solubility of isoproturon by its complexation with beta-cyclodextrin. Chemosphere, 51:811-816
31. Fernandes CM, Teresa Vieira M, Veiga FJ. (2002). Physicochemical characterization and in vitro dissolution behavior of nicardipine-cyclodextrins inclusion compounds. Eur J Pharm Sci, 15:79-88
32. Loukas YL, Vraka V, Gregoriadis G. (1998). Drugs, in cyclodextrins in liposomes: A novel approach to the chemical stability of drugs sensitive to hydrolysis. Int J Pharm, 162:137-142
33. Louise C, James M. (2000). Polymorphic from of a tachykinin receptor antagonist. US patent No. 6,096,742